Logo
Loading

Loading page data

Please wait a moment

Emailsales@persistencemarketresearch.com
UK

Second Floor, 150 Fleet Street,
London, EC4A 2DQ.

+44 203-837-5656
USA

108 W 39th Street, Ste 1006,
PMB2219, New York, NY 10018

+1 646-878-6329
India

IT Unit No. 504, 5th Floor, Icon
Tower, Baner, Pune - 411045.

+91 906 779 3500
Quick Links
CareersTerms & ConditionsReturn Policy Market Research Report
Customer FAQ’sPrivacy Policy Sitemap

Copyright © 2026 Persistence Market Research. All Rights Reserved

Connect With Us -
Request For Customization Radioligand Therapy Market by Isotope (Lutetium-177 (Lu-177), Actinium-225 (Ac-225), Iodine-131 (I-131), Radium-223, Gallium-68, Fluorine-18, Others), Target (Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Gastrin-Releasing Peptide Receptor (GRPR), Others), Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Lung Cancer, Pancreatic Cancer, Others), End-user, and Regional Analysis from 2026 - 2033